The ECHELON‐2 trial showed that the anti‐CD30 antibody‐drug conjugate brentuximab vedotin (BV) + CHP was superior to CHOP in PTCL, however only three patients are a promising treatment option. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.